ONCOLOGY Staff

Alicia Morgans, MD, discusses genomic testing and use of PARP inhibitors for metastatic castration-resistant prostate cancer.

John Kirkwood, MD, PhD, discusses the use of immunotherapy as a treatment option for melanoma, including ctDNA, and how to properly monitor responses.

Experts in prostate cancer discuss recent advances in the treatment of patients with metastatic castration-naive and metastatic castration-resistant prostate cancer and strategies for optimizing therapy.

Expert panelists follow a patient case to discuss locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy.

ONCOLOGY® recaps an Around the Practice program moderated by Sagar Lonial, MD, with additional panelists Morie A. Gertz, MD; Parameswaran Hari, MD, MS; and Andrzej Jakubowiak, MD, PhD.

A panel of experts reflect on how to treat patients with advanced renal cell carcinoma by reviewing clinical trial data and discussing patient cases.

Recommendations for treating patients with steroid-refractory chronic GVHD based on evidence demonstrated by the REACH3 trial.

A panel of experts discuss strategies for optimizing first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma.

As always, keep up with the latest issue of ONCOLOGY® to stay up-to-date on the latest practical and timely clinical information necessary to deliver the highest level of patient care.

The International Society of Gastrointestinal Oncology (ISGIO), hosted by Physicians’ Education Resource, LLC (PER®) presented the latest advances in the field of gastrointestinal cancer research.

Cesar A. Perez, MD, and Victoria M. Villaflor, MD, discuss tipifarnib in patients with head and neck cancers harboring HRAS mutations.

Brian T. Helfand, MD, PhD, and Steven E. Finkelstein, MD, discuss the potential of 18F-fluciclovine PET/CT to guide prostate cancer decision-making.

“We’ve been spoiled by 2 extraordinary experiences [in this setting]. Both tucatinib and trastuzumab deruxtecan are much better than anything we’ve had since we got pertuzumab for first-line therapy.” —SARA A. HURVITZ, MD, FACP

In this CancerNetwork® OncView™ program, faculty panelist Connie Batlevi, MD, PhD, explains the treatment options in this disease space and discusses a recent drug approval.

“We’re learning to understand how to leverage immunotherapy for a cure.”

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability–High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).

“These are priceless accomplishments that impact the lives of people.”

Kelly Valla, PharmD, BCOP, reviews the product profile of tazemetostat for the treatment of follicular lymphoma.

Kathryn Maples, PharmD, BCOP, discusses real-world implications of belantamab mafodotin in patients with pretreated multiple myeloma.

“Using science to guide therapy…has dropped the death rate in lung cancer historically.”

ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.

As genomic profiling becomes more and more essential as part of clinical decision making, clinicians are challenged to stay abreast of advancements in this space to improve patient outcomes and advance the field of precision oncology.

Experts discusses the treatment of patients with HER2-positive breast cancer in a virtual CancerNetwork® Around the Practice presentation,“Relapsed/Refractory HER2+ Metastatic Breast Cancer,” held January 21, 2021, and moderated by Adam M. Brufsky, MD, PhD.

“It’s a time for great hope with breast cancer, given the number of agents being evaluated now.” –Sara A. Hurvitz, MD